Brendon Hanson

Brendon Hanson is the Vice President of Discovery and Research Platforms at Hummingbird Bioscience. He leads the planning and implementation of the company’s early-stage discovery and development activities.

Brendon has been developing antibodies for nearly 30 years, initially to provide research reagents during his academic career. Moving to DSO National Laboratories in 2004, he was the Principal Scientist in the Biodefense Program, developing platforms for rapid therapeutic antibody discovery against infectious disease pathogens over the last 17 years. He then co-established and was later appointed Head of the Antibody Core Facility at the National University of Singapore’s Life Sciences Institute. Prior to joining Hummingbird, Brendon led efforts toward rapid discovery of potently neutralizing antibodies during the early stages of the COVID-19 pandemic.

Brendon holds a PhD in Biochemistry from La Trobe University (Australia). He has also authored over 50 peer-reviewed publications.